Literature DB >> 10233671

Human B cells secrete migration inhibition factor (MIF) and present a naturally processed MIF peptide on HLA-DRB1*0405 by a FXXL motif.

D Wymann1, M Blüggel, H Kalbacher, T Blesken, C A Akdis, H E Meyer, K Blaser.   

Abstract

A better knowledge of peptide structures interacting with major histocompatibility complex (MHC) molecules is of great interest for better understanding of the molecular basis of immune recognition. We have isolated naturally processed peptides from a continuously growing antigen-presenting Epstein-Barr virus-transformed human B-cell line. HLA-DR complexes were purified by specific affinity chromatography and complexed peptides were released by acid treatment. The isolated peptides were separated by reversed phase chromatography and fractions were analysed by Edman degradation at picomolar ranges. From 30 fractions that were examined seven peptides bound to the HLA-DRB1*0405 and two peptides from the human leucocyte antigen (HLA) class II associated invariant chain bound to HLA-DRB1*1302. In addition, a N-terminal beta-chain peptide of the 0405 allele was identified. Evaluation of amino acid sequences revealed a refined FXXL motif for the 0405 allele, in which F (phenylalanine) stands for any aromatic amino acid and L (leucine) can be exchanged by either I (isoleucine) or V (valine). In total, three fractions contained a peptide derived from the human migration inhibition factor (MIF), a pro-inflammatory cytokine that is normally produced by activated T lymphocytes and monocytes/macrophages. Indeed, cytokine analysis revealed high amounts of MIF secreted by the B-cell line, confirming that MHC class II expressing cells can present any intrinsic peptide that contains the distinct motif for HLA-binding. For MIF, the amino acid sequence Y36IAV39 represents the required binding motif for HLA-DRB1*0405. Nevertheless, it is the first time that cytokine fragments were found to bind to HLA molecules on human B cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233671      PMCID: PMC2326723          DOI: 10.1046/j.1365-2567.1999.00652.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  33 in total

1.  Intracellular transport of class II MHC molecules directed by invariant chain.

Authors:  V Lotteau; L Teyton; A Peleraux; T Nilsson; L Karlsson; S L Schmid; V Quaranta; P A Peterson
Journal:  Nature       Date:  1990-12-13       Impact factor: 49.962

2.  Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules.

Authors:  P A Roche; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

3.  The intensity of T cell receptor engagement determines the cytokine pattern of human allergen-specific T helper cells.

Authors:  J M Carballido; A Faith; N Carballido-Perrig; K Blaser
Journal:  Eur J Immunol       Date:  1997-02       Impact factor: 5.532

4.  Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding.

Authors:  A Stryhn; L O Pedersen; T Romme; C B Holm; A Holm; S Buus
Journal:  Eur J Immunol       Date:  1996-08       Impact factor: 5.532

5.  Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3.

Authors:  T Halder; G Pawelec; A F Kirkin; J Zeuthen; H E Meyer; L Kun; H Kalbacher
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

6.  Role for intracellular proteases in the processing and transport of class II HLA antigens.

Authors:  J S Blum; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

7.  Studies on the production of MIF and mitogenic factor using highly purified human T and B lymphocytes.

Authors:  R E Rocklin; L Chess; R P MacDermott; S F Schlossman; J R David
Journal:  Rheumatology       Date:  1975       Impact factor: 7.580

8.  A biological function for the XP motif within the N terminus of major histocompatibility complex class II-associated peptides.

Authors:  M Breloer; S Ehrlich; B Fleischer; A von Bonin
Journal:  Eur J Immunol       Date:  1996-08       Impact factor: 5.532

9.  Release of migration inhibitory factor from mouse T and B cells activated by insoluble phytomitogens.

Authors:  K Sugane; T Kasahara; K Shioiri-Nakano
Journal:  Jpn J Exp Med       Date:  1975-02

10.  Identification of a macrophage antigen-processing event required for I-region-restricted antigen presentation to T lymphocytes.

Authors:  K Ziegler; E R Unanue
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

View more
  4 in total

1.  Class I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation.

Authors:  Mitsuru Seki; Ryan LaCanna; Jeffery C Powers; Christine Vrakas; Fang Liu; Remus Berretta; Geena Chacko; John Holten; Pooja Jadiya; Tao Wang; Jeffery S Arkles; Joshua M Copper; Steven R Houser; Jianhe Huang; Vickas V Patel; Fabio A Recchia
Journal:  J Pharmacol Exp Ther       Date:  2016-06-27       Impact factor: 4.030

Review 2.  The p53 status in rheumatoid arthritis with focus on fibroblast-like synoviocytes.

Authors:  Mahdi Taghadosi; Mehrnoosh Adib; Ahmadreza Jamshidi; Mahdi Mahmoudi; Elham Farhadi
Journal:  Immunol Res       Date:  2021-05-13       Impact factor: 2.829

3.  Arrest Functions of the MIF Ligand/Receptor Axes in Atherogenesis.

Authors:  Sabine Tillmann; Jürgen Bernhagen; Heidi Noels
Journal:  Front Immunol       Date:  2013-05-16       Impact factor: 7.561

Review 4.  MIF and CXCL12 in Cardiovascular Diseases: Functional Differences and Similarities.

Authors:  Emiel P C van der Vorst; Yvonne Döring; Christian Weber
Journal:  Front Immunol       Date:  2015-07-21       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.